Life Sciences

  • October 28, 2025

    J&J Hit With $20M Verdict In Fla. Talc Trial

    A Florida jury on Tuesday awarded $20 million to the widow of a nephrologist who used Johnson & Johnson talcum powder for 50 years and died of mesothelioma, after a plaintiffs lawyer argued the company broke its "promise of purity."

  • October 28, 2025

    Exactech Gets Another $19M In DIP Funds Ahead Of Sale

    Joint implant maker Exactech Inc. received a Delaware bankruptcy judge's permission Tuesday to borrow an additional $19.1 million in its Chapter 11 case as the company works to complete an asset sale by the end of the week.

  • October 28, 2025

    Ex-Philips CEO Can't Undo Finding He Misled Shareholders

    A Brooklyn federal judge will not reverse a finding that a former CEO of health technology company Koninklijke Philips NV misled shareholders about the safety and compliance of a subsidiary's sleep and respiratory care products.

  • October 28, 2025

    Akin Beats Malpractice Claim Over Alleged IP Theft Plot

    A Third Circuit panel on Tuesday refused to revive a malpractice claim against Akin Gump Strauss Hauer & Feld LLP lodged in a lawsuit that accused attorneys of manipulating patent litigation to steal a former Cornell University graduate student's DNA sequencing intellectual property.

  • October 28, 2025

    4th Circ. Overturns Landmark W.Va. Opioid Verdict

    The Fourth Circuit on Tuesday overturned a key ruling by a West Virginia judge in the first federal bellwether in multidistrict opioid litigation that went in favor of the country's three biggest drug distributors, finding that the oversupply of opioids can create a public nuisance.

  • October 28, 2025

    Greenberg Traurig Adds Faegre Drinker Mass Tort Pro In NJ

    Greenberg Traurig LLP added to its products liability and pharmaceutical practices in New Jersey this week with the addition of a litigator and trial attorney from Faegre Drinker Biddle & Reath LLP who specializes in complex mass tort cases.

  • October 28, 2025

    Texas Accuses Tylenol Makers Of Hiding Autism Danger

    The Texas Attorney General's Office on Tuesday sued the makers of Tylenol, alleging they hid the risk that the drug could lead to autism while marketing acetaminophen as the safest pain relief option for pregnant women and young children.

  • October 27, 2025

    Whistleblower 'Horrified' By Novo Nordisk Drug Sales Tactics

    The whistleblower behind a federal lawsuit accusing Novo Nordisk of paying kickbacks to doctors and patients as part of a scheme to drive sales of its hemophilia drug NovoSeven took the witness stand Monday, telling jurors she was "horrified" at how the drugmaker's marketing team targeted doctors.

  • October 27, 2025

    Bros. Had No Fraud Intent In HIV Drug Scam, Fla. Jury Told

    Two Maryland brothers accused of orchestrating a roughly $100 million misbranded HIV drug scheme told a Florida federal jury Monday they had no intent to defraud, saying they were deceived by a co-conspirator who they made a partner in their company. 

  • October 27, 2025

    Teva To Pay $35M In Suit Over Delayed Generic Inhalers

    Teva Pharmaceuticals will pay $35 million to resolve claims from a coalition of union healthcare funds that say the company schemed to delay generic competition for its QVAR asthma inhalers, according to a motion for preliminary injunction filed in Massachusetts federal court.

  • October 27, 2025

    Acadia Pushes For Appeal Of Investors' Partial Early Win

    Acadia Healthcare Company Inc. is looking to appeal a partial early win granted to a proposed class of investors accusing the company of misleading them about the strength of its United Kingdom operations, arguing that the court's recent ruling presents controlling questions of law warranting immediate appellate review.

  • October 27, 2025

    LifeScan Gets Final OK On Ch. 11 Plan After Deal With PBMs

    A Texas bankruptcy judge on Monday granted confirmation of LifeScan Global Corp.'s Chapter 11 plan after the debtor reached an agreement with pharmacy benefit managers that resolved their objections, allowing the glucose-monitor maker to complete a deal to cut about $1.4 billion of debt.

  • October 27, 2025

    Feds Fight Union Bid To Protect Jobs During Gov't Shutdown

    The Trump administration is fighting a group of unions' request for a California federal judge to block the government from laying off federal workers during the shutdown, saying the injunction request from eight unions is far too broad.

  • October 27, 2025

    Fed. Circ. Won't Revive Heart Valve IP Suit Against Edwards

    Edwards Lifesciences won't have to face infringement litigation from Aortic Innovations over heart valve transplant technology, the Federal Circuit affirmed Monday.

  • October 27, 2025

    AbbVie Defends Challenge Of Colorado's Discount Drug Law

    AbbVie defended its lawsuit challenging a Colorado law it says conflicts with federal law by forcing manufacturers to sell drugs at steep discounts to Walgreens, CVS and other pharmacy chains, telling a federal judge that the state compels the biotech company to sell more discounted drugs than federal law requires.

  • October 27, 2025

    Judge Tosses Eli Lilly Suit Over Telehealth Weight Loss Drugs

    A California federal court has dismissed a lawsuit from Eli Lilly against a telehealth company and related entities over the compounding of its popular weight loss drugs Mounjaro and Zepbound, saying the pharmaceutical giant's complaint failed to plausibly allege claims under the Lanham Act and the state's false advertising and consumer protection laws.

  • October 27, 2025

    Samsung Infringed Smart Ring IP, Suit Says

    Smart ring maker Oura has hit Samsung with patent claims in Texas federal court, alleging the Korean electronics giant had been challenging Oura's patents in the U.S. before the launch of its allegedly infringing Samsung Galaxy Ring.

  • October 27, 2025

    Moderna Says Vax Efficacy Math Doesn't Show Investor Fraud

    An investor in vaccine giant Moderna Inc. has failed to show that the company misrepresented the efficacy of its RSV vaccine by pointing out that the U.S. Food and Drug Administration later recalculated the vaccine's efficacy, the company said in an effort to slip a proposed investor class action.

  • October 27, 2025

    Biotech Firm MapLight Inks $251M IPO Amid Shutdown

    Biotechnology company MapLight Therapeutics began trading publicly Monday after raising $251 million in its initial public offering, which marked a rare listing during the ongoing federal government shutdown.

  • October 27, 2025

    Catching Up With Delaware's Chancery Court

    The Delaware Chancery Court and Delaware Supreme Court saw another busy week of disputes spanning biotech milestones, reincorporation showdowns, shareholder voting schemes and cryptocurrency fiduciary rights.

  • October 27, 2025

    Ex-Magellan CEO Avoids Prison Over Faulty Lead Tests

    The former CEO of Magellan Diagnostics was sentenced in Massachusetts federal court Monday to a year of home confinement for failing to alert regulators to a problem in the company's lead-testing devices that resulted in inaccurately low lead levels being detected in blood samples.

  • October 27, 2025

    Covington Helps Novartis Buy Avidity Biosciences For $12B

    Swiss pharmaceutical giant Novartis AG has said it will buy Avidity Biosciences, a U.S. developer of therapeutics for muscle diseases, for approximately $12 billion in a move to boost its neuroscience portfolio.

  • October 24, 2025

    Pfizer Hit With More Suits Over Depo-Provera

    Three women sued Pfizer this week in Florida federal court, alleging its hormonal contraceptive birth control shot Depo-Provera caused their brain tumors in the latest claims that the major drugmaker failed to warn of the link.

  • October 24, 2025

    Ohio, Ky. Reps Again Pursue Bill To Make PTAB Optional

    A bipartisan pair of legislators in the U.S. House of Representatives are floating a bill that would give patent owners the ability to extinguish challenges to their intellectual property at the Patent Trial and Appeal Board before they start.

  • October 24, 2025

    GNC Franchisee Cos. Largely Lose Bid To Toss Award Order

    An international court judge has largely denied efforts by GNC franchisee businesses in Singapore and the Philippines to set aside an order enforcing arbitral awards totaling about $45 million that also enforced a contractual obligation to assign their 54 stores in Singapore to the health and wellness company.

Expert Analysis

  • Series

    Law School's Missed Lessons: Communicating With Clients

    Author Photo

    Law school curricula often overlook client communication procedures, and those who actively teach this crucial facet of the practice can create exceptional client satisfaction and success, says Patrick Hanson at Wiggam Law.

  • 3 Judicial Approaches To Applying Loper Bright, 1 Year Later

    Author Photo

    In the year since the U.S. Supreme Court overturned Chevron deference in its Loper Bright Enterprises v. Raimondo decision, a few patterns have emerged in lower courts’ application of the precedent to determine whether agency actions are lawful, say attorneys at Husch Blackwell.

  • Prepping For SEC's Changing Life Sciences Enforcement

    Author Photo

    By proactively addressing several risk areas, companies in the life sciences sector can position themselves to minimize potential exposure under the U.S. Securities and Exchange Commission's return to back-to-basics enforcement focused on insider trading and fraud, say attorneys at Morgan Lewis.

  • Series

    Adapting To Private Practice: From US Rep. To Boutique Firm

    Author Photo

    My transition from serving as a member of Congress to becoming a partner at a boutique firm has been remarkably smooth, in part because I never stopped exercising my legal muscles, maintained relationships with my former colleagues and set the right tone at the outset, says Mondaire Jones at Friedman Kaplan.

  • How Providers Can Brace For Drug Pricing Policy Changes

    Author Photo

    Though it's uncertain which provisions of the Trump administration's executive order aimed at addressing prescription drug costs will eventually be implemented, stakeholders can reduce potential negative outcomes by understanding pathways that could be used to effectuate the order's directives, say attorneys at McDermott.

  • Discretionary Denial Rulings May Spur Calls For PTAB Reform

    Author Photo

    The U.S. Patent and Trademark Office's recent decision in iRhythm Technologies v. Welch Allyn, denying inter partes review based on the patent owner's settled expectations that the patent would not be challenged, could motivate patent holders to seek Patent Trial and Appeal Board reform to preserve patent quality without burdening owners, say attorneys at Dechert.

  • Comparing New Neural Data Privacy Laws In 4 States

    Author Photo

    Although no federal law yet addresses neural privacy comprehensively, the combined effect of recent state laws in Colorado, California, Montana and Connecticut is already shaping the regulatory future, but a multistate compliance strategy has quickly become a gating item for those experimenting with neuro-enabled workplace tools, says Kristen Mathews at Cooley.

  • Spinoff Transaction Considerations For Biotech M&A

    Author Photo

    Amid current market challenges, boards and management teams of biotech companies can consider several strategies for maximizing value should a spinoff opportunity arise, but not without significant advance planning and careful implementation, particularly in cases that might qualify as tax-free, say attorneys at Paul Hastings.

  • Opinion

    Senate's 41% Litigation Finance Tax Would Hurt Legal System

    Author Photo

    The Senate’s latest version of the Big Beautiful Bill Act would impose a 41% tax on the litigation finance industry, but the tax is totally disconnected from the concerns it purports to address, and it would set the country back to a time when small plaintiffs had little recourse against big defendants, says Anthony Sebok at Cardozo School of Law.

  • Psychedelic Treatment Regs May Be At A Tipping Point

    Author Photo

    Recent scientific and public attention suggest that development of psychedelics as treatment for some conditions may be at a tipping point, which could bring on more rapid change and opportunities for stakeholders who may in the future benefit from greater access to safe and effective psychedelic medicines, say attorneys at King & Spalding.

  • Tips For Litigating Apex Doctrine Disputes Amid Controversy

    Author Photo

    Litigants once took for granted that deposition requests of high-ranking corporate officers required a greater showing of need than for lower-level witnesses, but the apex doctrine has proven controversial in recent years, and fights over such depositions will be won by creative lawyers adapting their arguments to this particular moment, say attorneys at Hangley Aronchick.

  • Series

    Performing As A Clown Makes Me A Better Lawyer

    Author Photo

    To say that being a clown in the Macy’s Thanksgiving Day Parade has changed my legal career would truly be an understatement — by creating an opening to converse on a unique topic, it has allowed me to connect with clients, counsel and even judges on a deeper level, says Charles Tatelbaum at Tripp Scott.

  • A Midyear Tuneup For Your Trade Secret Portfolio

    Author Photo

    Halfway through 2025, now is a good time for companies to thoroughly evaluate their trade secret portfolios and follow eight steps to reassess protection processes for confidential information, says Robert Jensen at Wolf Greenfield.

  • Focusing On Fluoride: From FDA To Class Action

    Author Photo

    A class action filed two days after the U.S. Food and Drug Administration announced plans to remove ingestible fluoride prescription drug products for children from the market may be the tip of the iceberg in terms of the connection between government pronouncements on safety and their immediate use as evidence in lawsuits, says Rachel Turow at Skadden.

  • Series

    Law School's Missed Lessons: Rejecting Biz Dev Myths

    Author Photo

    Law schools don’t spend sufficient time dispelling certain myths that prevent young lawyers from exploring new business opportunities, but by dismissing these misguided beliefs, even an introverted first-year associate with a small network of contacts can find long-term success, says Ronald Levine at Herrick Feinstein.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.